摘要
心力衰竭发病率和病死率很高,心脏再同步治疗(CRT)和植入式心律转复除颤器(ICD)治疗能够改善心力衰竭患者的临床症状,降低患者的再住院率,改善心脏重构,并提高患者的生存率。门控心肌灌注显像(GMPI)相位分析技术可以评价左心室收缩不同步性,门控正电子发射型计算机断层(PET)心肌代谢显像可以评估心肌存活和左心室收缩的同步性,123I-间位碘代苄胍(123I-MIBG)和11 C-羟基麻黄碱(11 C-HED)的心脏神经受体显像可以评价心力衰竭患者的心脏交感神经功能。
Heart failure(HF)is associated with a morbidity and mortality.Cardiac resynchronization therapy(CRT)and implantable cardiac defibrillator(ICD)treatment can improve clinical symptoms,reduce rehospitalization rate,ameliorate heart remodeling and increase survival rate in patients with HF.Left ventricular systolic dyssynchrony can be assessed by phase analysis of gated myocardial perfusion imaging(GMPI).Myocardial viability and left ventricular systolic synchrony can be assessed by gated positron emission tomography(PET).Sympathetic nerve function can be assessed by cardiac neuroreceptor imaging with 123I-meta-iodobenzyl guanidine(123I-MIBG)and 11C-hydroxyephedrine(11C-HED).
出处
《南昌大学学报(医学版)》
CAS
2015年第4期95-99,共5页
Journal of Nanchang University:Medical Sciences
基金
国家自然科学基金(81071177)
北京市科技计划首都临床特色应用研究(Z131107002213181)
关键词
心力衰竭
心脏再同步治疗
植入式心律转复除颤器
门控心肌灌注显像
相位分析
心脏神经受体显像
heart failure
cardiac resynchronization therapy
implantable cardiac defibrillator
gated myocardial perfusion imaging
phase analysis
cardiac neuroreceptor imaging